Drugs / binodenoson
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00944970 | Oct 2005 → Dec 2006 | coronary artery disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00944294 | Feb 2004 → Apr 2006 | coronary artery disorder | Pfizer | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | binodenoson | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00944970 ↗ |
| Known as | Corvue | ChEMBL registry synonym — accepted as the source's own label CHEMBL1950554 ↗ |
| Known as | MRE-0470 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1950554 ↗ |
| Known as | Wrc0470 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1950554 ↗ |
| Action | Activate | “Adenosine A2a receptor agonist” CHEMBL1950554 ↗ |
| Modality | Small molecule | — CHEMBL1950554 ↗ |
| Route | Intravenous | “30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg)” NCT00944294 ↗ |
| Target | ADORA2A | “Adenosine A2a receptor agonist” CHEMBL1950554 ↗ |